| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697945 | Clinical Oncology | 2016 | 8 Pages |
Abstract
Although selective VEGFR inhibitors are associated with similar overall survival as multikinase inhibitor sorafenib, they show significant improvement in progression-free survival, regardless of first-line or later use, and ORR compared with sorafenib. Tolerability due to toxicities is similar.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S.K. Kang, A. Volodarskiy, E.L. Ohmann, A.V. Balar, S. Bangalore,